AIN457 + Placebo
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-infectious Uveitis
Conditions
Non-infectious Uveitis
Trial Timeline
Aug 1, 2010 → Jul 1, 2011
NCT ID
NCT01090310About AIN457 + Placebo
AIN457 + Placebo is a phase 3 stage product being developed by Novartis for Non-infectious Uveitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT01090310. Target conditions include Non-infectious Uveitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01090310 | Phase 3 | Terminated |
| NCT01132612 | Phase 2 | Completed |
| NCT01071252 | Phase 2 | Completed |
| NCT01051817 | Phase 2 | Completed |
| NCT00809614 | Phase 2 | Completed |
| NCT00809159 | Phase 2 | Completed |
| NCT00805480 | Phase 2 | Completed |
| NCT00770965 | Phase 2 | Completed |
| NCT00584740 | Phase 2 | Terminated |
| NCT00669916 | Phase 1/2 | Completed |
| NCT00669942 | Phase 1/2 | Completed |
Competing Products
10 competing products in Non-infectious Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Adalimumab | AbbVie | Approved | 85 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 52 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 77 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 52 |
| ESK-001 | Alumis | Phase 2 | 47 |
| Topical Prednisolone Acetate 1% | Ocular Therapeutix | Approved | 80 |
| FAI insert + Sham injection | EyePoint Pharmaceuticals | Phase 3 | 72 |
| FAI Insert administered using the Mk II inserter + FAI Insert administered using the Mk I inserter | EyePoint Pharmaceuticals | Phase 3 | 72 |
| ADX-102 Ophthalmic Solution (0.5%) + Vehicle of ADX-102 Ophthalmic Solution | Aldeyra Therapeutics | Phase 3 | 69 |
| NS2 + Prednisolone acetate ophthalmic suspension (1%) | Aldeyra Therapeutics | Phase 2 | 44 |